Arbekacin - Nobelpharma

Drug Profile

Arbekacin - Nobelpharma

Alternative Names: Arbekacin sulfate - Nobelpharma; Nonsense readthrough compound; NPC-14

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nobelpharma
  • Class Aminoglycosides; Antibacterials; Cyclohexanols; Cyclohexylamines; Hexosamines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Duchenne muscular dystrophy

Most Recent Events

  • 25 Aug 2016 Arbekacin is still in phase II trials for Duchenne muscular dystrophy in Japan (IV)
  • 02 Sep 2015 Nobelpharma completes enrolment in its phase II trial for Duchenne muscular dystrophy in Japan (NCT01918384)
  • 29 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top